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Summary
Alcoholic liver disease (ALD) is the most prevalent cause of advanced liver disease in Europe and 
is the leading cause of death among adults with excessive alcohol consumption. There is a dose-
response relationship between the amount of alcohol consumed and the risk of ALD. The relative 
risk of cirrhosis increases in subjects who consume more than 25 g/day. The burden of alcohol-
attributable liver cirrhosis and liver cancer is high and is entirely preventable. Health agencies 
should develop population-based policies to reduce the prevalence of harmful and/or hazardous 
alcohol consumption and foster research in this field to provide new diagnostic and therapeutic 
tools. Disease progression of patients with ALD is heavily influenced by both genetic and 
environmental factors. Non-invasive methods for the diagnosis of fibrosis have opened new 
perspectives in the early detection of advanced ALD in asymptomatic patients. Alcoholic hepatitis, 
the most severe form of ALD, carries a high short-term mortality (around 30–50% at 3 months). 
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis but duration 
of therapy should be adapted to early response. Liver transplantation is the best option for patients 
with severe liver dysfunction. However, alcohol relapse after transplantation remains a critical 
issue and drinking habits of transplanted patients need to be routinely screened.
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Burden of alcohol liver disease
Abusive alcohol consumption is a major cause of preventable morbidity and mortality 
worldwide. Besides organ damage, alcohol consumption is a major cause of accidents and 
violence [1]. The health consequences of alcohol consumption vary according to the extent 
and method of usage (excessive or not, acute or chronic), and depend on numerous 
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environmental and individual factors. Demographic characteristics, the amount of alcohol 
intake, frequency, duration and profile of consumption vary among alcohol drinkers [2]. In 
men, daily drinking is associated with an increased risk of alcoholic cirrhosis. Interestingly, 
recent alcohol consumption rather than earlier in life consumption is associated with higher 
risk of alcoholic cirrhosis [3]. Alcohol drinkers consuming up to 2 drinks/day (men) or 1 
drink/day (women) are defined as moderate drinkers and do not disclose increased risk of 
organ damage compared to abstainers. Daily consumption above those limits can lead to 
health, personal and social problems. This definition does not capture the pattern of binge 
drinking that is quite different from that of chronic drinkers. There is wide heterogeneity in 
the definition of binge drinking, according to the threshold of alcohol intake per episode. 
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) proposed a consensual 
definition of binge drinking episodes as the consumption of 5 or more drinks (male) or 4 or 
more drinks (female) in about 2 h [4]. This definition fails to recognize the amount of 
alcohol intake per binge episode. Moreover, the possibility of having several binges during 
the same day is not included. Finally, a binge alcohol drinker can have periods of continuous 
alcohol use. The phenomenon of binge drinking continues to grow in Western countries, and 
is particularly striking in beer- and spirit-drinking cultures in the UK and northern Europe 
[5]. Between 1993 and 2001 in the USA, binge drinking episodes per person per year 
increased by 17%, with the highest rates occurring among youth aged 18 to 25 years [6]. In 
the UK, the Health Survey for England (HSE) reported that 57% of young males were binge 
drinkers [7]. Most European countries exhibit the same trend towards an increase in binge 
drinking, even in southern countries. As an example, one French 17-year-old population 
reported having had binge drinking episodes over the previous month, of one, three or ten 
times in 45.8%, 17.9%, and 2.2% of cases, respectively [8]. Since 1998, American college 
students aged 18–24 have had a significantly higher increase in alcohol-related deaths than 
population totals for the same age group [9]. Thus, public health policies should be targeted 
towards young people, though they may be less receptive to the prevention messages against 
this pattern of drinking [10]. Up until now, policies have failed to reduce binge drinking in 
adolescents and adults, which remains an important health objective in Western countries. 
The question arises as to whether specialists in liver disease should be concerned by the 
increase in binge drinkers. However, data concerning the impact of binge drinking on the 
liver are limited because it has been insufficiently investigated [8,11].
There is a significant disparity in the sex distribution of deaths attributable to excessive 
alcohol consumption. As an example, 11% of deaths in men and 1.8% in women in Europe 
are attributable to alcohol [2]. Chronic alcohol consumption may lead to cirrhosis and is 
associated with an increased risk for hepatocellular carcinoma (HCC) [4]. Alcoholic liver 
disease (ALD) is the most prevalent cause of advanced liver disease in Europe and cirrhosis 
is the leading cause of death due to alcohol among adults [2]. There is a dose-response 
relationship between the volume of alcohol consumed with the risk of ALD. Previous 
epidemiological studies strongly suggested a considerable association between alcohol 
consumption and cirrhosis and emphasized the correlation between severity and duration of 
alcohol abuse and the presence of cirrhosis. Above a threshold of daily alcohol consumption, 
the risk of developing cirrhosis increases exponentially. However, the threshold value of 
daily alcohol consumption associated with increased risk of cirrhosis has long been 
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controversial. The amount of alcohol intake can be expressed in g/day, number of drinks 
(each drink contains 14 g of alcohol) or alcohol units (each unit has 8 g of alcohol in the UK 
or 14 g in USA). A meta-analysis observed that consumption of more than 25 g/day 
increases the relative risk of cirrhosis [12]. This threshold has been validated in the Dionysos 
project assessing the prevalence of alcoholic cirrhosis in a cohort derived from a general 
population of two cities in northern Italy [13]. Six thousand nine hundred and seventeen 
adult subjects were asked about their alcohol consumption. Twenty-one percent of the 
population had a daily alcohol consumption of more than 30 g/day. The rate of cirrhosis was 
significantly higher in patients who consumed ≥30 g/day (2.2%) than among abstainers or 
those with consumption <30 g/day: 2.2% vs. 0.08%. The risk of cirrhosis increased with the 
amount of alcohol consumed. Subjects who consumed more than 120 g/day had the highest 
risk of cirrhosis, with a prevalence of 13.5%.
Liver diseases are an important cause of global burden of mortality and morbidity [14,15]. 
The burden of liver diseases in North America and Europe is mainly attributable to alcohol 
whereas in Africa and Asia viral hepatitis is the dominant force. In 2010, cirrhosis accounted 
for more than 493,300 deaths (156,900 female and 336,400 male deaths) and for more than 
14.5 million DALYs (disability-adjusted life year) (around 4.1 million DALYs for women 
and 10.4 million DALYs for men) [14–16]. In addition, around 82,000 deaths (around 
14,000 female and 66,000 male deaths) and 2.1 million DALYs were due to alcohol-induced 
liver cancer [14–16]. The weight of alcohol on liver-related mortality is strongly supported 
by data showing a relationship between standard liver death rate and overall alcohol 
consumption in several European countries (Fig. 1) [17].
Variations in alcohol consumption largely contribute to cirrhosis mortality trends and its 
variability across countries [18,19]. Also, reduction in alcohol consumption in most 
countries is followed by a decrease in cirrhosis mortality. In North America, Australia and 
Southern Europe alcohol consumption decreased in recent years, leading to comparable 
decline in cirrhosis mortality [18,20–22]. Conversely, the high rates of cirrhosis mortality in 
Hungary and other countries of central and Eastern Europe are mainly due to their high per 
capita alcohol consumption [18]. The marked rises in cirrhosis mortality in Ireland and the 
UK (particularly Scotland) are related to the fact that total recorded alcohol consumption in 
Britain doubled between 1960 and 2002 [10]. Indeed, one study compared age-standardized 
mortality rates for cirrhosis in the UK with the rates from 12 Western European countries for 
the period between 1955 and 2001 [10]. UK standardized mortality rates for cirrhosis 
increased in men from 3.4 between 1957 and 1961, to 14.1 per 100,000 per year between 
1997 and 2001, with the same trend in women, whereas it decreased in other European 
countries. Cirrhosis mortality rates in Scotland are among the highest in Western Europe, 
with mortality rates in men and women of 42.2 and 20 per 100,000 per year, respectively 
[10]. Another study obtained records of all patients in a longitudinal database of 13 million 
subjects followed in general practice [23]. This study confirmed a 45% increase in the 
incidence of cirrhosis in the UK during the last decade.
These studies indicate that the burden of alcohol-attributable liver cirrhosis and liver cancer 
is high and entirely preventable. Health agencies should develop population-based policies 
to reduce levels of harmful and/or hazardous consumption and provide financial support for 
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research aimed at developing improved therapies for patients with ALD [2,16]. Public health 
policies should include taxation escalations for alcoholic beverages that should be partially 
used to cover patient costs and to develop new therapies for alcohol use disorders and ALD. 
Several approaches have been used, including policies to decrease availability of alcohol by 
limiting the hours and places of sale and establish minimum age purchase laws [2]. 
Moreover, several studies have shown that the rising price of alcohol decreases morbidity 
and mortality [24,25]. The advent of cheap alcohol has had a particularly deleterious effect 
in the UK and Ireland, which have, in turn, lead to efforts to curb excess consumption by 
raising the minimum price of alcohol or banning the sale of alcohol below cost (in England 
and Wales). Recent modeling studies suggest that the former method is more likely to be 
effective [26]. Other more nuanced approaches may be necessary in societies where alcohol 
use is linked to production within the family home, especially in Eastern Europe.
Natural history of alcoholic liver disease: from steatosis to cirrhosis
The spectrum of ALD comprises simple steatosis, alcoholic steatohepatitis (ASH), 
progressive fibrosis, cirrhosis and the development of HCC Fig. 2. Several studies suggested 
that incidence of HCC is lower in alcoholic cirrhosis than in viral cirrhosis. The risk of HCC 
persists in cirrhotic patients even among those that remain abstinent. Although up to 90% of 
heavy drinkers develop steatosis, only a minority of those with steatosis progress to ASH 
and 10–20% eventually develop cirrhosis [27,28]. Steatosis is usually asymptomatic and 
rapidly reversible with abstinence [28]. Continued heavy alcohol consumption, however, 
leads in some patients to liver inflammation characterized by the infiltration of 
polymorphonuclear cells (PMN), hepatocyte damage often described as ballooning, and 
Mallory-Denk’s bodies, both of which define ASH. Some patients develop liver fibrosis 
(20–40%) and cirrhosis (10–20%), which confers a high risk of complications (ascites, 
variceal bleeding, hepatic encephalopathy, renal failure and bacterial infections) [29,30].
In the last decades, major advances have been made in our understanding of the factors that 
influence ALD progression [31–34]. The natural history of ALD cannot be separated the 
natural history of alcoholism. Alcohol use, remission and relapse comes in many different 
patterns and needs to be observed over many years [35]. This applies both to those in 
possession of their native liver, and the post-transplant patient with alcoholism [36]. Disease 
progression varies according to genetic and environmental factors. The major link of people 
with a genetic predisposition to develop ALD is supported by the observation of 
concordance rates for alcoholism and alcohol-induced liver fibrosis in monozygotic twins of 
26.3 and 14.6, respectively [37]. Recent studies observed that variations in PNPLA3, which 
encodes patatin-like phospholipase domain-containing protein 3, strongly influence the 
development of advanced liver fibrosis among Mexican and Caucasian populations [37–40]. 
Importantly, PNPLA3 polymorphisms can be considered to be the only confirmed and 
replicated genetic risk factor for ALD. This genetic factor also influences the development 
of HCC [41]. Despite the large number of studies that have assessed the role of genetic 
variation in susceptibility to ALD, a large-scale genome-wide association study of factors 
associated with ALD remains to be performed given the potential biases of previous studies 
[42]. Most published reports include a limited number of patients who lack a well-defined 
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phenotype, the investigation of only a few genes and have crucial methodological 
weaknesses.
Although several translational studies have evaluated the risk of cirrhosis, the natural history 
of ALD remains only partially explored due to the lack of prospective studies of large 
cohorts with the goal of assessing progression of liver damage. A translational study 
comprising over 2000 hospitalized excessive heavy drinkers with modified results in liver 
laboratory tests investigated by liver biopsy showed that 34% of these subjects presented 
with alcohol-induced cirrhosis, 46% with fatty liver with/without fibrosis, 9% with acute 
alcohol-induced hepatitis and 11% with a normal liver [43]. When the progression of 
fibrosis was expressed in terms of duration of exposure, the progression of fibrosis was 
estimated by dividing the fibrosis score by the time of exposure. In heavy drinkers, the risk 
of cirrhosis reached 50% at 61 years of age, and the likelihood of developing cirrhosis in 
50% of cases was observed after 35 years, with a shorter time of progression to cirrhosis 
among women than men [44]. Based on an analysis of all the published data, cirrhosis 
occurs in approximately 20% of hospitalized patients with excessive alcohol consumption.
The presence of steatosis typically precedes the development of fibrosis [45] but the 
influence of fat accumulation on progression of fibrosis is not well known. The long-term 
survival of patients with isolated steatosis is clearly reduced compared to that of abstinent 
controls. After a mean follow-up of approximately 10 years, patients with alcoholic steatosis 
died more frequently than those with non-alcoholic fatty liver disease (74% vs. 25%) and 
more patients developed cirrhosis (21% vs. 1%) [46]. Twenty-five percent of the observed 
deaths among heavy drinkers were associated with cirrhosis and 75% were attributed to 
other diseases related to alcohol.
Patients with underlying severe fibrosis or cirrhosis and heavy alcohol intake can present a 
form of acute-on-chronic liver failure called alcoholic hepatitis (AH) [29]. This is 
characterized by an abrupt rise in serum bilirubin levels, jaundice and liver-related 
complications. Previously, it was considered that AH could occur in patients with mild 
underlying liver disease. However, more recent studies using tru-cut needles have shown that 
the majority of patients with severe AH have underlying cirrhosis [47]. Patients with severe 
forms of AH show high short-term mortality around 30–50% at 3 months. Patients with AH 
disclosed the fastest progression of fibrosis and consequently an increased risk of liver-
related death [45]. Among other factors, obesity is an independent risk factor for progression 
to cirrhosis. Heavy drinkers who are overweight for at least 10 years have a 2-fold risk of 
developing cirrhosis [43]. While it is not surprising that obesity predisposes to alcohol-
induced fatty liver, it is somehow surprising that it favors the development of AH. This 
association suggests that insulin resistance probably exacerbates the deleterious effects of 
alcohol in the liver. In fact, hyperglycemia is an independent predictor of progression of 
fibrosis in heavy drinkers [48]. Finally, there are some reports suggesting that moderate 
drinking may have beneficial effect on the livers of obese subjects [49].
There is a clear need to perform prospective large follow-up studies to identify the main 
genetic and environmental factors that influence disease progression in patients with ALD. 
There are few clinical trials in patients with early forms of ALD and the natural history of 
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this disease is poorly understood. Disease progression is usually silent until heavy drinkers 
develop jaundice or liver decompensation that, in many cases, occurs in the context of an 
episode of AH. The course of ALD frequently alternates between periods of complications 
and liver failure due to excessive drinking and compensated disease as a result of periods of 
alcohol abstinence.
Diagnosis of alcoholic liver disease
In its early stages, ALD is a silent disease and can only be detected by laboratory tests or 
imaging techniques. There are few programs aimed at early detection of ALD at its 
asymptomatic stages. Some patients with early ALD can show stigmata of alcohol abuse 
such as bilateral parotid gland hypertrophy, muscle wasting, malnutrition, Dupuytren’s sign, 
and signs of peripheral neuropathy. In patients with cirrhosis, most physical findings are not 
specific of the etiology. However, some signs such as gynecomastia and extensive spider 
angiomas may be more frequently seen in those with alcohol as the main cause of liver 
disease. The diagnosis of ALD is frequently suspected upon documentation of excessive 
alcohol consumption (>40–50 g/day) and the presence of clinical and/or biological 
abnormalities suggestive of liver injury. Laboratory blood tests such as mean corpuscular 
volume, gamma glutamyl transpeptidase (GGT) and aspartate amino transferase (AST) can 
indicate early ALD whereas advanced ALD is suspected if there is decreased albumin, 
increased INR, elevated bilirubin level or low platelet count. There are several laboratory 
markers that estimate persistent alcohol intake. Among them, carbohydrate deficient 
transferrin and GGT are the most frequently used markers to detect previous alcohol 
consumption [50]. In patients with ALD, the AST/ALT ratio typically is greater than 1 [51]. 
This ratio is typically greater than 2 in AH and can also be found in patients with advanced 
cirrhosis regardless of the etiology.
Liver biopsy is not clearly indicated in patients with early stages of ALD or when 
established cirrhosis is revealed by clinical, analytical and imaging data. The liver biopsy 
can be done percutaneously in most patients but requires a transjugular approach in patients 
with a low platelet count and/or a prolonged prothrombin time. The precise indications of 
liver biopsy are not well established in routine practice. However, it is suggested in patients 
with aggressive forms of ALD such as AH requiring specific therapies (e.g., corticosteroids 
and/or pentoxifylline) and in patients with other cofactors suspected of contributing to liver 
disease. In the setting of clinical trials, the assessment of liver histology by performing a 
liver biopsy is recommended. The typical findings in patients with ALD include steatosis, 
hepatocellular damage (ballooning and/or Mallory-Denk bodies), an inflammatory infiltrate 
basically composed of PMN cells that predominates in the lobules, and a variable degree of 
fibrosis and lobular distortion that may progress to cirrhosis [52].
For the assessment of liver fibrosis in patients with ALD, there are non-invasive methods 
including serum markers and liver stiffness measurements. Most non-invasive tests have 
been largely validated in patients with hepatitis C, while few studies have included patients 
with ALD. Thus, AST to platelet ratio index (APRI), FibroTest®, Fibrometer®, Hepascore®, 
and Fibrosure® can be useful in patients with ALD [53]. They are useful to distinguish 
between mild and severe fibrosis, but have limited utility in intermediate degrees of fibrosis. 
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In terms of prognostic value, FibroTest® (AUROC for survival = 0.79 ± 0.04), Fibrometer® 
(0.80 ± 0.04) and Hepascore® (0.78 ± 0.04) had a prognostic value equivalent to liver biopsy 
(0.77 ± 0.04) [54]. Transient elastography (FibroScan®) is commonly used to assess fibrosis 
in patients with chronic liver disease. FibroScan® calculates an estimate, expressed in kPa 
(kilopascals), for the stiffness from the measurement of wave velocity. The diagnostic 
threshold with the optimal diagnostic value for the detection of cirrhosis varies between 12.5 
and 14.6 kPa in studies including chronic hepatitis C [55]. The diagnostic value of 
FibroScan® for the detection of cirrhosis has been evaluated in excessive drinkers in two 
independent studies [56,57]. In these studies, the elasticity was correlated with fibrosis stage 
and the diagnostic value of FibroScan® confirmed by AUROC close to 0.9. The optimal 
thresholds for the diagnosis of cirrhosis were respectively 19.5 and 22.6 kPa [56,57]. It is 
important to note that these thresholds, although close together, are very different from those 
proposed for the detection of cirrhosis in chronic carriers of the hepatitis B and C virus. Of 
note, elevated liver stiffness values in patients with ALD and AST serum levels >100 U/L 
should be interpreted with caution because of the possibility of falsely elevated liver stiffness 
as a result of superimposed ASH [58]. Moreover, recent alcohol consumption can also 
elevate liver stiffness, perhaps related to the vasodilatory effects of alcohol [59]. Imaging 
techniques can also be used to assess the severity of ALD. Ultrasonography, MRI, and CT 
are useful to detect fatty liver, advanced fibrosis/cirrhosis as well as signs of portal 
hypertension [60]. Moreover, they are useful for the screening and assessment of 
complications such as ascites and portal vein thrombosis. Among those methods, ultrasound 
is the most used due to its low cost. However, its sensitivity and specificity is low especially 
when steatosis is mild. MRI and MR spectroscopy are reliable tools for assessing the amount 
of steatosis but their use is limited by high cost [61].
Management of alcoholic hepatitis
Providing more efficacious therapies for patients with AH is one of the most urgent needs in 
clinical hepatology. The current first line therapy (i.e. prednisolone) was proposed in 1971, 
but novel targeted therapies are needed [62]. Currently, there are no reliable non-invasive 
diagnostic tools for AH in patients with decompensated ALD. The classical profile of AH 
comprises elevated serum AST up to twice the upper limit of the normal range, although 
rarely above 300 IU/ml, with an AST/ALT ratio typically greater than 2 [29,63]. Biological 
parameters indicating impaired liver function include hypoalbuminemia, elevated bilirubin, 
high INR and prothrombin time. The presence of acute kidney injury, often due to 
superimposed hepatorenal syndrome, is associated with a high risk of death [29,64]. In 
addition, patients with AH frequently disclose leukocytosis and elevated temperature 
resulting from a systemic inflammatory response syndrome.
In routine practice as in many published clinical trials, the diagnosis of AH relies on clinical 
and biological criteria. However, such strategy carries a 10–50% risk of misclassifying 
patients with or without ASH [65–67]. In the setting of clinical trials, the diagnosis of AH 
through liver biopsy has been recommended by EASL guidelines [2], and liver biopsy may 
be considered in patients with aggressive forms of ALD requiring specific interventions or 
when the diagnosis remains in doubt. A transjugular route is often preferred due to frequent 
coexisting ascites and/or coagulopathy. Recently, a histological scoring system has been 
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proposed for predicting short-term survival in patients with AH. The resulting Alcoholic 
Hepatitis Histological Score comprises four parameters that are independently associated 
with patients’ survival: fibrosis stage, PMN infiltration, type of bilirubinostasis and the 
presence of megamitochondria (Fig. 3). By combining these parameters in a semi-
quantitative manner, this histological score is able to stratify patients into low, intermediate, 
or high risk for death within 90 days [47].
Viral hepatitis and bacterial infections should be ruled out, particularly spontaneous bacterial 
peritonitis. Importantly, the clinical manifestations of spontaneous bacterial peritonitis and 
the episode of AH are often similar (abdominal pain, fever, leukocytosis). Doppler 
ultrasound is required to exclude biliary or vascular disorders and HCC. Severe AH may 
progress to multisystem organ failure and as mentioned above the advent of acute kidney 
injury is associated with a bad prognosis [68]. In this setting, the use of AKIN criteria for 
acute kidney injury is more sensitive than the traditional criteria of renal failure (i.e. 
creatinine >1.5 mg/dl) for predicting multiorgan dysfunction and death [69]. AH patients are 
also at risk of acute kidney injury due to the use of nephrotoxic radiocontrast agents, 
aminoglycosides and non-steroidal anti-inflammatories.
Significant mortality and morbidity in Europe and North America are attributable to AH 
[70,71], with around 57,000 hospital admissions for AH in the US in 2007, which accounted 
to 0.71% of all admissions [70,71]. However, the diagnosis of AH is frequently overlooked, 
especially in patients admitted for gastrointestinal bleeding or sepsis. In-hospital mortality 
fluctuates from 6.8% to 15% [70,71]. Patients at significant risk of early death can be 
identified by prognostic models. The available prognostic models include the Maddrey’s 
discriminant function (DF), the Model for End-Stage Liver Disease (MELD), the Glasgow 
AH (GAH) score, and the ABIC score [72–74]. The most widely used is the DF, which is 
calculated as 4.6 × (prothrombin time patient − prothrombin time control) + serum bilirubin 
[75]. A DF value ≥32 is indicative of evaluated short-term mortality around 20–35% at 1 
month. The MELD discloses accuracy similar to DF [73] and a MELD of 21 has 75% 
sensitivity and specificity in predicting 90-day mortality. The GAH score incorporates age, 
serum bilirubin, blood urea nitrogen, prothrombin time, and peripheral white blood cell 
count, and has been shown to accurately predict 28-day mortality [74]. The ABIC uses age, 
bilirubin, INR, and creatinine to estimate a 90-day risk of mortality, and can categorize 
patients into low (0%), intermediate (30%), and high (75%) risk of death [72]. The MELD 
has been evaluated in US cohorts, the GAH in populations from the UK, and the ABIC in 
Spain.
Early identification of patients with a substantial improvement in hepatic function is of 
interest in the management of severe AH [76]. After 7 days of medical therapy with 
prednisolone, physicians may identify responders using the Lille model [76]. The Lille 
model is highly predictive of death at 6 months and a score above 0.45 predicted 75% of 
deaths [76,77]. Clinical practice guidelines therefore recommend stopping corticosteroids 
after one week in those with an unfavorable Lille score, as the risks of continued therapy 
likely outweigh the benefits [2,76,78].
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The therapeutic management of AH patients includes general and specific measures. The 
achievement of alcohol abstinence is the cornerstone of treatment of AH patients and 
requires active management of alcohol use disorders. Symptoms of alcohol withdrawal 
should be monitored, prevented and treated. Intensive nutritional intervention is required to 
correct protein-calorie malnutrition [79] through high calorie meals and supplements, or 
through enteral feedings if necessary and thiamine should be administered when considering 
the increased risk of Wernicke’s encephalopathy in alcoholic patients [80]. Patients with 
severe AH should be admitted for initial management when considering the increased risk of 
early deaths, and often need admission to an intensive care unit. Infections are exceedingly 
common in severe AH [78] and should be routinely screened with at least chest x-ray, 
urinoanalysis, and cultures of blood, urine and ascites [78]. Empiric antibiotics may be 
administered if there is a high suspicion of infection. Prevention of acute kidney injury, 
another frequent complication indicating increased risk of early mortality [64], should be 
performed using volume expansion with crystalloid/albumin. Interestingly, patients with 
systemic inflammatory response are at high risk of developing acute kidney injury [64].
The European and American guidelines proposed prednisolone or pentoxifylline [81] as first 
line therapeutic options for patients with severe AH [82,83]. However, two recent studies 
called into question the use of pentoxifylline. A head-to-head randomized study showed that 
the use of pentoxifylline does not have beneficial effects on survival compared to 
prednisolone [84]. In a large randomized controlled trial (STOPAH) that includes more than 
1000 patients that was presented during the 2014 AASLD The Liver Meeting®, 
pentoxifylline was no better than placebo in terms of short-term mortality [85]. However, 
this study excluded patients with more severe forms of AH (acute kidney injury, severe 
sepsis, severe encephalopathy, etc.). Therefore, it is unclear if pentoxifylline is also 
ineffective in patients with very severe forms.
Corticosteroids have been used in the treatment of AH for more than 40 years [75,86–90]. 
The most studied formulation is prednisolone 40 mg daily for one month, with or without a 
taper. Although the clinical trials suffer from heterogeneity and high risk of bias, a meta-
analysis from individual data observed that corticosteroids improved survival in patients 
with a high DF [91]. This study confirmed the need for adapting corticosteroid therapy to 
response to treatment. A subgroup analysis was performed according to the percentile 
distribution of the Lille score. This approach identified three patterns of responses; 
complete, partial and null, with significant differences in survival benefit: 91% vs. 79% vs. 
53%, respectively. Survival impact of corticosteroids was significant in complete and partial 
responders, whereas it appeared negligible in null responders [91]. This new classification 
raises questions concerning management of severe AH. There are two issues that should be 
raised. First, the survival benefit from corticosteroid therapy is transient, as suggested by the 
recent STOPAH trial [85]. And second, the use of prednisolone increases the risk of 
pulmonary infections, especially invasive aspergillosis [92]. Therefore, it is important to 
develop new therapies that offer a sustained response and do not favor potentially lethal 
infections.
It seems clear that corticosteroids may be sufficient in complete responders and that novel 
pharmacological therapies are required for intermediate responders. Several attempts have 
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been made to combine steroids with other drugs. The combination of both pentoxifylline and 
prednisolone offers no benefit [93] and there are no available rescue medical therapies for 
non-responders [29,77]. A recent randomized trial showed that the combination of N-
acetylcysteine with prednisolone reduced 1-month mortality (8% vs. 24%) and incidence of 
hepatorenal syndrome and infection [94]. The favorable safety profile of N-acetylcysteine 
makes it an appealing option, although confirmatory studies are needed. In non-responders 
to corticosteroids, a liver transplantation was traditionally contraindicated, since patients 
could not complete a 6-month period of abstinence. When following a strict 6-month rule for 
transplant eligibility, most patients die before a transplant can be indicated [95]. This fact 
prompted several experts in the field to challenge this policy and to perform a prospective 
study of early liver transplantation in highly selected patients with good social support and 
positive prognosis from a psychological point of view. Performing a salvage liver transplant 
in selected patients with AH non-responding to medical therapy dramatically improve 
survival [96]. These results support future evaluation of early liver transplantation in a 
carefully-selected subgroup of patients with severe AH non-responding to medical therapy 
[2]. This controversial indication is increasingly being accepted by liver centers yet 
confirmatory studies are needed.
Liver transplantation in alcoholic cirrhotic patients
ALD is a major indication for liver transplantation worldwide. Patients needing a transplant 
due to ALD often present at the time of transplantation multisystemic effects of long-term 
ethanol abuse [97]. These comorbidities include malnutrition, vitamin deficiencies, non-
immune hemolytic anemia, peripheral and central neural system abnormalities, nephropathy, 
muscle wasting due to alcoholic myopathy, and others. Therefore, the integral care of the 
transplanted patient with ALD ideally requires a multidisciplinary approach.
Most liver programs require a 6-month period of abstinence prior to evaluation of alcoholic 
patients [82,98,99]. The rationale of this strategy is to allow disease regression in patients 
with recent alcohol abstinence and to ensure proper alcohol counseling in order to prevent 
relapse after the liver transplantation. As for other causes of decompensated liver disease, 
patients are listed if the MELD score is ≥15. In patients with ALD, the survival benefit 
among transplant recipients arises only from this threshold [100]. Alcohol abstinence is a 
critical issue and drinking habits of transplanted patients need to be routinely screened by 
physicians with tools of proven reliability. However, there is no consensus concerning the 
definition of alcohol relapse [101,102]. For some experts, any drinking is considered a 
relapse, whereas others have defined excessive drinking as relapse because only this 
drinking pattern is associated with alcohol-induced liver injury. The definition of a relapse as 
any alcohol intake after liver transplantation contrasts with the literature on addiction 
medicine in which relapse is considered only in the presence of heavy drinking recurrence. 
This lack of consensus in definition of alcohol relapse explains why the rate of relapse after 
liver transplantation varies among studies ranging from 10% to 50% [103,104]. A meta-
analysis showed no differences in the proportion of transplant recipients with ALD that 
drank after a liver transplant compared with those with non-ALD: 4% vs. 5% at 6 months 
and 17% vs. 16% at 12 months [105]. However, transplant patients with ALD were more 
likely to drink excessively [105]. In terms of liver injury, occasional or moderately heavy 
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drinking does not impact graft function or patient survival [106,107] whereas the deleterious 
effect of excessive drinking is established at long-term. Indeed, recipients who resume 
abusive drinking have shorter long-term survival than abstinent recipients or patients with 
minor relapse [108] and recurrence of ALD is the main cause of death.
Mortality and morbidity after liver transplantation in ALD patients is similar to patients with 
other etiologies [109]. A recent study demonstrated that survival outcome of living donor 
liver transplantation in ALD patients is comparable with that of deceased donor liver 
transplantation. Interestingly, less than 2% of patients died of alcohol abuse, suggesting that 
alcohol relapse is not a major problem in patients receiving a living donor liver 
transplantation [110]. The cause of death after transplantation for ALD differs compared to 
non-ALD recipients. In particular, cardiovascular causes and de novo malignancies are 
significantly over-represented in the patients transplanted for ALD [111]. There is not a clear 
association between new-onset cancers and alcohol relapse, suggesting that other 
environmental factors such as cigarette smoking and obesity can certainly play a role.
There are few data demonstrating the effectiveness of preventive measures in the 
development of comorbidities in these patients. Psychosocial efforts during the pre- and 
post-liver transplantation periods should be focused not only on alcohol relapse but also on 
preventing and treating modifiable risk factors such as obesity and cigarette smoking. A 
recent proof of concept study showed that smoking withdrawal after liver transplantation had 
a protective effect against the development of neoplasia in ALD transplant patients [112]. 
Further studies assessing the impact of specific measures and programs for smoking 
cessation should be performed in this patient population.
There is a current trend to tailor the immunosuppression in patients with ALD by 
minimizing the exposure to calcineurin inhibitors and promoting the use of mTOR inhibitors 
(rapamycin and everolimus). The rationale is that calcineurin inhibitors are known to favor 
cardiovascular events and mTOR inhibitors may promote decreased tumor growth and 
angiogenesis. Although some recent retrospective studies support this strategy in patients 
with ALD [113], well-designed studies should assess the optimal immunosuppressive 
regimens in these patients.
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Fig. 1. Relationship between standard liver death rate and overall alcohol consumption in several 
European countries
The relationship between standard liver death rate (SDR) (per 100,000) and overall alcohol 
consumption (pure alcohol litres per capita, age 15+) in the four countries in the EU 
(pre-2004) with the largest rises or falls in liver deaths between 1970 and 2008. Data from 
the World Health Organization, European Health for All database (HFA-DB): http://
data.euro.who.int/hfadb/. Reproduced with permission from [17].
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Fig. 2. Natural history of alcoholic liver disease from steatosis to cirrhosis and hepatocellular 
carcinoma (HCC)
The percentage represents the patients who progress from one stage to the next. Most 
patients with persistent alcohol abuse develop some degree of hepatic steatosis. If the 
alcohol abuse persists, liver fibrosis progressively develops, ultimately resulting in cirrhosis. 
Cirrhosis can lead to severe complications related to portal hypertension (ascites, variceal 
bleeding and encephalopathy), bacterial infections and also predisposes to HCC. The 
development of alcoholic steatohepatitis (ASH) predisposes patients to progress to advanced 
liver fibrosis, and when this develops in patients with severe disease it results in AH.
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Fig. 3. The Alcoholic Hepatitis Histological Score (AHHS) allows prognostic stratification of 
patients with biopsy-proven AH
AHHS categories are as follows: mild, 0–3; intermediate, 4–5; severe, 6–9. The Kaplan-
Maier graph shows 90-day survival in each the three categories. Reproduced with 
permission from [47].
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